JP2024533034A - 治療剤を局所的に送達するための薬物送達システムおよびその使用 - Google Patents

治療剤を局所的に送達するための薬物送達システムおよびその使用 Download PDF

Info

Publication number
JP2024533034A
JP2024533034A JP2024506186A JP2024506186A JP2024533034A JP 2024533034 A JP2024533034 A JP 2024533034A JP 2024506186 A JP2024506186 A JP 2024506186A JP 2024506186 A JP2024506186 A JP 2024506186A JP 2024533034 A JP2024533034 A JP 2024533034A
Authority
JP
Japan
Prior art keywords
drug delivery
delivery system
mmol
group
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533034A5 (https=
Inventor
ウー，グオローン
ジャーン，ウエイジアン
フエン，リチュン
ジャーン，ハオ
リー，ダフェン
Original Assignee
コヴァル バイオファーマ （シャンハイ） カンパニー，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コヴァル バイオファーマ （シャンハイ） カンパニー，リミテッド filed Critical コヴァル バイオファーマ （シャンハイ） カンパニー，リミテッド
Publication of JP2024533034A publication Critical patent/JP2024533034A/ja
Publication of JP2024533034A5 publication Critical patent/JP2024533034A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024506186A 2021-09-16 2022-09-14 治療剤を局所的に送達するための薬物送達システムおよびその使用 Pending JP2024533034A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/118666 2021-09-16
CN2021118666 2021-09-16
PCT/CN2022/118658 WO2023040879A1 (en) 2021-09-16 2022-09-14 Drug delivery system for locally delivering therapeutic agents and uses thereof

Publications (2)

Publication Number Publication Date
JP2024533034A true JP2024533034A (ja) 2024-09-12
JP2024533034A5 JP2024533034A5 (https=) 2025-08-28

Family

ID=85602430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506186A Pending JP2024533034A (ja) 2021-09-16 2022-09-14 治療剤を局所的に送達するための薬物送達システムおよびその使用

Country Status (9)

Country Link
US (1) US20240398963A1 (https=)
EP (1) EP4402152A1 (https=)
JP (1) JP2024533034A (https=)
KR (1) KR20240056728A (https=)
CN (1) CN118019750A (https=)
AU (1) AU2022348759A1 (https=)
CA (1) CA3227319A1 (https=)
IL (1) IL311382A (https=)
WO (1) WO2023040879A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002095A1 (en) * 2024-06-26 2026-01-02 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally controlled release of therapeutic agents and uses thereof
CN119735627B (zh) * 2024-12-25 2025-10-21 西北农林科技大学 甾体并3，4二氢吡咯吡嗪酮衍生物及其合成方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009096749A (ja) * 2007-10-16 2009-05-07 Konica Minolta Holdings Inc コレステロール誘導体、リポソーム及びｘ線用造影剤
EP3142705B1 (en) * 2014-05-15 2020-08-19 Agency For Science, Technology And Research Polymer-flavonoid conjugate and uses thereof

Also Published As

Publication number Publication date
CN118019750A (zh) 2024-05-10
EP4402152A1 (en) 2024-07-24
US20240398963A1 (en) 2024-12-05
WO2023040879A1 (en) 2023-03-23
KR20240056728A (ko) 2024-04-30
CA3227319A1 (en) 2023-03-23
IL311382A (en) 2024-05-01
AU2022348759A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
AU2025256194A1 (en) Lymphatic system-directing lipid prodrugs
CN115867319B (zh) 用于局部递送治疗剂的药物递送系统以及其用途
JP2024533034A (ja) 治療剤を局所的に送達するための薬物送達システムおよびその使用
JP7693948B2 (ja) ε－ポリ－Ｌ－リジンをベースとする薬物コンジュゲート、その中間体及びその用途
EP4729509A1 (en) Ionizable lipid for muscle-specific delivery
WO2016168568A1 (en) Derivatives of amphotericin b
WO2014027777A2 (ko) 신규한 우르솔릭산 유도체 및 이의 제조 방법
AU2021421161B2 (en) Ligand compounds, conjugates, and applications thereof
ES2968413T3 (es) Compuesto de glicósido de lactulosa, procedimiento de preparación y utilización del mismo
RU2847196C1 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
RU2847196C9 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
CN117957238A (zh) 氟维司群衍生物及其制备方法和医药用途
HK40110475A (zh) 用於局部递送治疗剂的药物递送系统以及其用途
CA3237677C (en) Epsilon-poly-l-lysine-based drug conjugate, intermediate thereof, and application thereof
RU2849554C2 (ru) Конъюгат производного ε-поли-l-лизина с лекарственным средством, промежуточные соединения и их применение
AU2024202698A1 (en) Three cluster galactose type compound, conjugate, making method and use thereof
HK40107352A (zh) 用於局部递送治疗剂的药物递送系统以及其用途
HK40107352B (zh) 用於局部递送治疗剂的药物递送系统以及其用途
WO2026002095A1 (en) Drug delivery system for locally controlled release of therapeutic agents and uses thereof
CN119213008A (zh) 加奈索酮的前药
CN121368610A (zh) 一种聚乙二醇药物及其制备方法和应用
Amitai et al. Quaternary-Lipophilic Carbamates with Blood Brain Barrier Permeability as Potential Drugs for Memory Impairment Associated with Cholinergic Deficiency

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250820